JP2015506678A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506678A5 JP2015506678A5 JP2014548965A JP2014548965A JP2015506678A5 JP 2015506678 A5 JP2015506678 A5 JP 2015506678A5 JP 2014548965 A JP2014548965 A JP 2014548965A JP 2014548965 A JP2014548965 A JP 2014548965A JP 2015506678 A5 JP2015506678 A5 JP 2015506678A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- loh
- megabase
- cancer cells
- pair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 121
- 201000011510 cancer Diseases 0.000 claims description 121
- 210000004027 cell Anatomy 0.000 claims description 96
- 210000003917 human chromosome Anatomy 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 57
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 25
- 239000012661 PARP inhibitor Substances 0.000 claims description 25
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 25
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 25
- 210000000349 chromosome Anatomy 0.000 claims description 24
- 239000012623 DNA damaging agent Substances 0.000 claims description 23
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 23
- 238000011269 treatment regimen Methods 0.000 claims description 21
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 20
- 210000003765 sex chromosome Anatomy 0.000 claims description 20
- 238000004590 computer program Methods 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 16
- -1 radiation Substances 0.000 claims description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 10
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical group NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 10
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 10
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 10
- 206010033128 Ovarian cancer Diseases 0.000 claims description 10
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 10
- 229960004679 doxorubicin Drugs 0.000 claims description 10
- 229960001904 epirubicin Drugs 0.000 claims description 10
- 201000004101 esophageal cancer Diseases 0.000 claims description 10
- 229950002133 iniparib Drugs 0.000 claims description 10
- 229960004768 irinotecan Drugs 0.000 claims description 10
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 10
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 claims description 10
- 229960000572 olaparib Drugs 0.000 claims description 10
- 229960000303 topotecan Drugs 0.000 claims description 10
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108700040618 BRCA1 Genes Proteins 0.000 claims description 8
- 108700010154 BRCA2 Genes Proteins 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 230000007547 defect Effects 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 7
- 101150072950 BRCA1 gene Proteins 0.000 claims description 6
- 101150008921 Brca2 gene Proteins 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 6
- 229940127089 cytotoxic agent Drugs 0.000 claims description 6
- 231100000518 lethal Toxicity 0.000 claims description 6
- 230000001665 lethal effect Effects 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 238000004393 prognosis Methods 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 102000036365 BRCA1 Human genes 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 190000008236 carboplatin Chemical compound 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- IIMIOEBMYPRQGU-UHFFFAOYSA-L picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 claims description 4
- 229950005566 picoplatin Drugs 0.000 claims description 4
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108050006400 Cyclin Proteins 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000010998 test method Methods 0.000 claims 5
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161578713P | 2011-12-21 | 2011-12-21 | |
| US61/578,713 | 2011-12-21 | ||
| US201261654402P | 2012-06-01 | 2012-06-01 | |
| US61/654,402 | 2012-06-01 | ||
| PCT/US2012/071380 WO2013096843A1 (en) | 2011-12-21 | 2012-12-21 | Methods and materials for assessing loss of heterozygosity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076503A Division JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506678A JP2015506678A (ja) | 2015-03-05 |
| JP2015506678A5 true JP2015506678A5 (https=) | 2016-02-04 |
| JP6325453B2 JP6325453B2 (ja) | 2018-05-16 |
Family
ID=48669561
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014548965A Active JP6325453B2 (ja) | 2011-12-21 | 2012-12-21 | ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2018076503A Active JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2020079997A Active JP7128853B2 (ja) | 2011-12-21 | 2020-04-30 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2022130844A Active JP7595619B2 (ja) | 2011-12-21 | 2022-08-19 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2024205398A Active JP7844597B2 (ja) | 2011-12-21 | 2024-11-26 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076503A Active JP6700333B2 (ja) | 2011-12-21 | 2018-04-12 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2020079997A Active JP7128853B2 (ja) | 2011-12-21 | 2020-04-30 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2022130844A Active JP7595619B2 (ja) | 2011-12-21 | 2022-08-19 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
| JP2024205398A Active JP7844597B2 (ja) | 2011-12-21 | 2024-11-26 | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9388472B2 (https=) |
| EP (3) | EP2794907B2 (https=) |
| JP (5) | JP6325453B2 (https=) |
| CN (2) | CN107267598B (https=) |
| AU (4) | AU2012358244A1 (https=) |
| BR (1) | BR112014015152A2 (https=) |
| CA (1) | CA2860312C (https=) |
| DK (1) | DK2794907T4 (https=) |
| ES (1) | ES2759533T5 (https=) |
| FI (1) | FI2794907T4 (https=) |
| WO (1) | WO2013096843A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3012329B1 (en) | 2010-06-18 | 2017-10-25 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| JP6117194B2 (ja) | 2011-06-17 | 2017-04-19 | ミリアド・ジェネティックス・インコーポレイテッド | アレル不均衡を評価するための方法および材料 |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) * | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| CA2958801A1 (en) | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| WO2016185406A1 (en) | 2015-05-19 | 2016-11-24 | Nadathur Estates Pvt. Ltd. | Method for identification of a deficient brca1 function |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| EP3452937B1 (en) | 2016-05-01 | 2025-10-22 | Genome Research Limited | Method of characterising a dna sample |
| JP7224185B2 (ja) * | 2016-05-01 | 2023-02-17 | ゲノム・リサーチ・リミテッド | Ｄｎａサンプルを特徴付ける方法 |
| GB201607629D0 (en) * | 2016-05-01 | 2016-06-15 | Genome Res Ltd | Mutational signatures in cancer |
| CN107287285A (zh) * | 2017-03-28 | 2017-10-24 | 上海至本生物科技有限公司 | 一种预测同源重组缺失机制及患者对癌症治疗响应的方法 |
| US11830579B2 (en) | 2017-07-25 | 2023-11-28 | Sophia Genetics Sa | Methods for detecting biallelic loss of function in next-generation sequencing genomic data |
| CN112805563B (zh) * | 2018-05-18 | 2025-06-13 | 约翰·霍普金斯大学 | 用于评估和/或治疗癌症的无细胞dna |
| IT201900013335A1 (it) * | 2019-07-30 | 2021-01-30 | Menarini Silicon Biosystems Spa | Metodo per analizzare la perdita di eterozigosi (loh) a seguito di amplificazione totale del genoma basata su un sito di restrizione deterministico (drs-wga) |
| CN114787374A (zh) * | 2019-10-29 | 2022-07-22 | 斯坦福大学托管董事会 | 基于对治疗的分子反应的治疗方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| CN112226495B (zh) * | 2020-12-18 | 2021-03-16 | 北京迈基诺基因科技股份有限公司 | 一种dna同源重组异常的检测方法及其应用 |
| WO2022150063A1 (en) * | 2021-01-10 | 2022-07-14 | Act Genomics (Ip) Co., Ltd. | Homologous recombination deficiency determining method and kit thereof |
| US20240026462A1 (en) * | 2021-01-10 | 2024-01-25 | Ying Ja CHEN | Homologous recombination deficiency determining method and kit thereof |
| CN113466417B (zh) * | 2021-05-13 | 2023-03-21 | 柳州东风容泰化工股份有限公司 | 一种氟尿嘧啶的制备纯度评估方法及系统 |
| US12188961B2 (en) | 2022-07-29 | 2025-01-07 | International Business Machines Corporation | Method for accurate pad contact testing |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
| WO2025173014A1 (en) | 2024-02-16 | 2025-08-21 | Onecell Diagnostics India Private Limited | A method for selecting ovarian cancer patients for parp inhibitor treatment |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| DE3630497A1 (de) | 1986-09-08 | 1988-03-10 | Behringwerke Ag | Cis-platin-komplexe, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische mittel |
| DK252688A (da) | 1987-05-08 | 1988-11-09 | Sankyo Co | Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse |
| US4996337A (en) | 1987-06-23 | 1991-02-26 | American Cyanamid Company | Synthesis of cisplatin analogs |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5434256A (en) | 1988-11-22 | 1995-07-18 | Board Of Regents, The University Of Texas System | Diamine platinum complexes as antitumor agents |
| US4946954A (en) | 1989-01-17 | 1990-08-07 | Georgetown University | Platinum pharmaceutical agents |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| AU647741B2 (en) | 1989-12-01 | 1994-03-31 | Regents Of The University Of California, The | Methods and compositions for chromosome-specific staining |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| ATE247471T1 (de) | 1991-11-15 | 2003-09-15 | Smithkline Beecham Corp | Cisplatin und topotecan enthaltende zusammensetzung als antitumor. |
| US5858662A (en) | 1993-04-05 | 1999-01-12 | University Of Utah Research Foundation | Diagnosis of Williams syndrome and Williams syndrome cognitive profile by analysis of the presence or absence of a LIM-kinase gene |
| WO1995003335A1 (en) * | 1993-07-26 | 1995-02-02 | K.O. Technology, Inc. | Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| US5587384A (en) | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
| US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| US5539083A (en) | 1994-02-23 | 1996-07-23 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid combinatorial libraries and improved methods of synthesis |
| US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
| US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
| GB9620209D0 (en) | 1996-09-27 | 1996-11-13 | Cemu Bioteknik Ab | Method of sequencing DNA |
| GB9626815D0 (en) | 1996-12-23 | 1997-02-12 | Cemu Bioteknik Ab | Method of sequencing DNA |
| WO1998041531A2 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
| US6214821B1 (en) | 1998-03-05 | 2001-04-10 | Washington State University Research Foundation | Methods and composition for the inhibition of cancer cells |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| GB9808145D0 (en) | 1998-04-17 | 1998-06-17 | Zeneca Ltd | Assay |
| WO2000009759A1 (en) | 1998-08-17 | 2000-02-24 | The Burnham Institute | Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis |
| US6465177B1 (en) | 1998-10-26 | 2002-10-15 | John Wayne Cancer Institute | Detection of loss of heterozygosity in tumor and serum of melanoma patients |
| US6534293B1 (en) | 1999-01-06 | 2003-03-18 | Cornell Research Foundation, Inc. | Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing |
| US6261775B1 (en) | 1999-04-09 | 2001-07-17 | The Regents Of The University Of California | Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma |
| US6274320B1 (en) | 1999-09-16 | 2001-08-14 | Curagen Corporation | Method of sequencing a nucleic acid |
| DE60131903T2 (de) | 2000-10-24 | 2008-11-27 | The Board of Trustees of the Leland S. Stanford Junior University, Palo Alto | Direkte multiplex charakterisierung von genomischer dna |
| US7858331B2 (en) | 2000-11-03 | 2010-12-28 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| JP4323802B2 (ja) | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| IL163600A0 (en) | 2002-03-01 | 2005-12-18 | Ravgen Inc | Methods for detection of genetic disorders |
| AU2003291281A1 (en) | 2002-11-01 | 2004-06-07 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| EP1578994A2 (en) | 2002-11-11 | 2005-09-28 | Affymetrix, Inc. | Methods for identifying dna copy number changes |
| US20070004621A1 (en) | 2003-02-12 | 2007-01-04 | Viji Shridhar | Bex4 nucleic acids, polypeptides, and method of using |
| US20040170983A1 (en) * | 2003-02-27 | 2004-09-02 | Danenberg Kathleen D. | Methods of determining a chemotherapuetic regimin based on loss of heterozygosity at the thymidylate synthase locus |
| WO2004083816A2 (en) | 2003-03-14 | 2004-09-30 | John Wayne Cancer Institute | Loss of heterozygosity of the dna markers in the 12q22-23 region |
| WO2005002508A2 (en) | 2003-06-11 | 2005-01-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| CN100412084C (zh) | 2003-07-02 | 2008-08-20 | 獀洛克斯股份有限公司 | 热稳定的结晶盐酸表柔比星及其制造方法 |
| US7531530B2 (en) | 2003-07-25 | 2009-05-12 | Cancer Research Technology Limited | Therapeutic compounds |
| AU2004270655B2 (en) | 2003-08-13 | 2011-03-24 | University Of South Florida | Methods for inhibiting tumor cell proliferation |
| ATE491953T1 (de) | 2003-09-15 | 2011-01-15 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| US20080108057A1 (en) | 2004-06-22 | 2008-05-08 | Griffith Jeffrey K | Allelic imbalance in the diagnosis and prognosis of cancer |
| CA2584723A1 (en) | 2004-10-22 | 2006-05-04 | Redpath Integrated Pathology, Inc. | Enhanced amplifiability of minute fixative-treated tissue samples, minute stained cytology samples, and other minute sources of dna |
| US20070070349A1 (en) | 2005-09-23 | 2007-03-29 | Helicos Biosciences Corporation | Optical train and method for TIRF single molecule detection and analysis |
| US8105768B2 (en) | 2005-03-09 | 2012-01-31 | Abbott Laboratories | Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number |
| US20060234264A1 (en) | 2005-03-14 | 2006-10-19 | Affymetrix, Inc. | Multiplex polynucleotide synthesis |
| ES2404311T3 (es) | 2005-04-12 | 2013-05-27 | 454 Life Sciences Corporation | Métodos para determinar variantes de secuencias usando secuenciación ultraprofunda |
| WO2006116341A1 (en) | 2005-04-21 | 2006-11-02 | Alza Corporation | Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes |
| WO2006128195A2 (en) | 2005-05-27 | 2006-11-30 | Dana-Farber Cancer Institute | Methods of diagnosing and treating cancer by detection of chromosomal abnormalities |
| ATE488507T1 (de) | 2005-06-30 | 2010-12-15 | Bionumerik Pharmaceuticals Inc | Platinanaloga mit monoazolligand |
| JP5477888B2 (ja) | 2005-09-21 | 2014-04-23 | バイオアレイ ソリューションズ リミテッド | 単鎖プライマ−プロモータ−セレクタ構造とｉｖｔを用いたメッセージ発生量及び対立遺伝子コピー数の決定 |
| US20080262062A1 (en) | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| EP2134855A4 (en) | 2007-03-12 | 2011-01-05 | Dana Farber Cancer Inst Inc | USES OF FANCI AND FANCI MODULATING AGENTS IN PROGNOSIS, DIAGNOSIS AND CANCER THERAPY |
| WO2009033178A1 (en) | 2007-09-07 | 2009-03-12 | Fluidigm Corporation | Copy number variation determination, methods and systems |
| ES2504690T3 (es) * | 2007-10-03 | 2014-10-08 | Eisai Inc. | Compuestos inhibidores de PARP, composiciones y métodos de uso |
| US7732491B2 (en) | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| RU2010128107A (ru) | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| US20090246789A1 (en) | 2008-03-25 | 2009-10-01 | University Of South Carolina | Gene Mutation Profiling of CSMD1 |
| WO2009148528A2 (en) † | 2008-05-30 | 2009-12-10 | Millennium Pharmaceuticals, Inc. | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment |
| JP5570516B2 (ja) | 2008-10-31 | 2014-08-13 | アッヴィ・インコーポレイテッド | 遺伝子コピー数の変化のパターンに基づいた結腸直腸癌のゲノム分類 |
| US8206910B2 (en) * | 2008-12-08 | 2012-06-26 | The Cleveland Clinic Foundation | Targets for use in diagnosis, prognosis and therapy of breast cancer |
| KR100925337B1 (ko) | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| EP2491139A1 (en) | 2009-10-19 | 2012-08-29 | Stichting Het Nederlands Kanker Instituut | Predicting benefit of anti-cancer therapy via array comparative genomic hybridization |
| CA2798657A1 (en) | 2010-02-24 | 2011-09-01 | Alexander Gutin | Diagnostic methods involving loss of heterozygosity |
| EP3012329B1 (en) | 2010-06-18 | 2017-10-25 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| WO2012019000A2 (en) | 2010-08-04 | 2012-02-09 | On-Q-ity | Biomarkers for the identification monitoring and treatment of ovarian cancer |
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| KR102759126B1 (ko) | 2010-12-30 | 2025-01-24 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| JP6117194B2 (ja) | 2011-06-17 | 2017-04-19 | ミリアド・ジェネティックス・インコーポレイテッド | アレル不均衡を評価するための方法および材料 |
| BR112014015152A2 (pt) | 2011-12-21 | 2017-07-04 | Myriad Genetics Inc | métodos e materiais para a avaliação da perda de heterozigosidade |
| CA2864481C (en) | 2012-02-23 | 2020-07-14 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| WO2013182645A1 (en) | 2012-06-07 | 2013-12-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| AU2014248007B2 (en) | 2013-04-05 | 2020-03-26 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| WO2015086473A1 (en) | 2013-12-09 | 2015-06-18 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| CN105917007A (zh) | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| CA2958801A1 (en) * | 2014-08-15 | 2016-02-18 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| JP7259274B2 (ja) * | 2018-11-12 | 2023-04-18 | ソニーグループ株式会社 | 情報処理装置、情報処理方法、及びプログラム |
-
2012
- 2012-12-21 BR BR112014015152A patent/BR112014015152A2/pt not_active IP Right Cessation
- 2012-12-21 JP JP2014548965A patent/JP6325453B2/ja active Active
- 2012-12-21 CA CA2860312A patent/CA2860312C/en active Active
- 2012-12-21 CN CN201710172605.2A patent/CN107267598B/zh active Active
- 2012-12-21 ES ES12860530T patent/ES2759533T5/es active Active
- 2012-12-21 EP EP12860530.0A patent/EP2794907B2/en active Active
- 2012-12-21 EP EP19199341.9A patent/EP3660161B1/en active Active
- 2012-12-21 EP EP24191594.1A patent/EP4497824A3/en active Pending
- 2012-12-21 FI FIEP12860530.0T patent/FI2794907T4/fi active
- 2012-12-21 CN CN201280070358.0A patent/CN104160037B/zh active Active
- 2012-12-21 DK DK12860530.0T patent/DK2794907T4/da active
- 2012-12-21 AU AU2012358244A patent/AU2012358244A1/en not_active Abandoned
- 2012-12-21 WO PCT/US2012/071380 patent/WO2013096843A1/en not_active Ceased
-
2014
- 2014-06-18 US US14/307,708 patent/US9388472B2/en active Active
-
2016
- 2016-06-24 US US15/192,497 patent/US10612098B2/en active Active
-
2018
- 2018-04-12 JP JP2018076503A patent/JP6700333B2/ja active Active
- 2018-08-02 AU AU2018211277A patent/AU2018211277B2/en active Active
-
2020
- 2020-02-24 US US16/799,797 patent/US12595513B2/en active Active
- 2020-04-30 JP JP2020079997A patent/JP7128853B2/ja active Active
- 2020-08-28 AU AU2020223754A patent/AU2020223754B2/en active Active
-
2022
- 2022-08-19 JP JP2022130844A patent/JP7595619B2/ja active Active
- 2022-09-08 AU AU2022228167A patent/AU2022228167B2/en active Active
- 2022-12-14 US US18/081,586 patent/US20230111438A1/en active Pending
-
2024
- 2024-11-26 JP JP2024205398A patent/JP7844597B2/ja active Active
-
2025
- 2025-03-21 US US19/087,361 patent/US20250215509A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506678A5 (https=) | ||
| JP7595619B2 (ja) | ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料 | |
| Marchini et al. | Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections | |
| ES2862331T3 (es) | Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer | |
| ES3039109T3 (en) | Methods and materials for assessing homologous recombination deficiency | |
| Ueda et al. | Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis | |
| Ghodousi et al. | MicroRNA‐326 and microRNA‐200c: Two novel biomarkers for diagnosis and prognosis of pediatric acute lymphoblastic leukemia | |
| Giulietti et al. | Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis | |
| US9410206B2 (en) | Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer | |
| den Brok et al. | Homologous recombination deficiency in breast cancer: a clinical review | |
| ES2777228T3 (es) | Métodos para evaluar la deficiencia de recombinación homóloga y predecir la respuesta al tratamiento del cáncer | |
| CN105308189B (zh) | 响应于抗癌疗法的肿瘤细胞标志物 | |
| US20140162887A1 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| CN105986031B (zh) | 肿瘤易感62基因及其应用 | |
| Zhou et al. | Identification of driver copy number alterations in diverse cancer types and application in drug repositioning | |
| Liu et al. | Development of a novel serum exosomal MicroRNA nomogram for the preoperative prediction of lymph node metastasis in esophageal squamous cell carcinoma | |
| US10676791B2 (en) | Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma | |
| US20240336977A1 (en) | Microrna-regulated biomarkers and drug targets for improving diagnosis and treatment of lung or breast cancer | |
| CN106480078A (zh) | 一组胃癌腹膜转移标志物及其用途 | |
| He et al. | Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune-and immunogenic cell death-related lncRNAs | |
| He et al. | Systematic analysis to identify the MIR99AHG-has-miR-21-5p-EHD1 CeRNA regulatory network as potential biomarkers in lung cancer | |
| CN109628600A (zh) | 一种用于早期乳腺癌诊断的生物标志物 | |
| Pan et al. | MicroRNA expression profiling of Chinese follicular lymphoma by microarray: A preliminary study | |
| Wang et al. | Methylation associated miR-1246 contributes to poor prognosis in gliomas treated with temozolomide | |
| CN116083579B (zh) | 用于非小细胞肺癌诊断的circRNA-miRNA-mRNA调控网络及其应用 |